Arthritis drug trial offers hope for autoimmune dryness disease
NCT ID NCT07281456
Summary
This study is testing if a drug called tofacitinib, already used for rheumatoid arthritis, is safe and can help control the symptoms of Sjogren's Syndrome. About 60 adults with mild to moderate Sjogren's will take the pill twice a day for 28 weeks to see if it reduces their disease activity and improves symptoms like dry mouth and joint pain. The main goal is to check for side effects, while also measuring changes in symptoms and body-wide inflammation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.